Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA

Sun Pharmaceutical Industries — Ranbaxy Laboratories — Q4 FY14 Earnings Presentation

18 slides from Sun Pharmaceutical Industries's earnings presentation, Feb 5, 2014

  1. Slide 1: Financial Results: October – December 2013 (Q4)

    Ranbaxy Laboratories Limited FINANCIAL RESULTS: October – December 2013 (Q4) YTD December 31, 2013 (YTD Dec) ARUN SAWHNEY CEO & MD Dept. 05 Feb 2014Name Post Results Conference Call Privileged and Confidential

  2. Slide 2: Safe Harbor

    Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “p

  3. Slide 3: Regulatory Development at Toansa

    Regulatory Development at Toansa  Toansa manufacturing plant was issued a Form 483 with certain observations and was subsequently included under certain provisions of the Consent Decree by the US FDA  The Company will work with the US FDA to resolve the concerns  Strict action to be taken upon co

  4. Slide 4: Key Achievements for Quarter 4, FY14

    1/2 Key Achievements for Quarter 4, FY14 Financial  Base business sales continued to grow over the corresponding quarter  Margin improvement continued during the quarter 9% 28,590 26,708 Percent Rs. Mn 2% Q4 2012 Q4 FY14 Q4 2012 Q4 FY14 Sales EBITDA/ Sales % Growth calculated on Constant Forex Pri

  5. Slide 5: Highlights: Quarter 4, FY14

    2/2 Highlights: Quarter 4, FY14 Business  Branded category sales Rs.14,791 Mn  52% of sales for the Quarter  Generic including API sales Rs.13,798 Mn  India:  Primary sales grew in the backdrop of  USA: pricing policy changes  Strong sales growth in Absorica™  EMs  East Europe sales grew on

  6. Slide 6: Functional Performance

    Functional Performance Manufacturing and Regulatory  Toansa manufacturing plant was issued a Form 483 with certain observations and was subsequently included under certain provisions of the Consent Decree by the US FDA  The Company will work with the US FDA to resolve the concerns  Strict action

  7. Slide 7: Other Areas

    Other Areas Research & Development  Regulatory Filings and approvals  DF filings: 63; DF approvals: 34  3 ANDA filed in USA; YTD Dec 2013: 10 ANDA filings Derivatives Position  Exposure down to ~$665 Mn as on 31 Dec 2013 from ~$763 Mn in Q3 2013. Maturity: ~$33 Mn/month Debt  Debt $980 Mn; Cash

  8. Slide 8: Financial Performance

    Ranbaxy Laboratories Limited Financial Performance FINANCIAL RESULTS: October – December 2013 (Q4 FY14) YTD December 31, 2013 (YTD Dec) Dept. Name Privileged and Confidential

  9. Slide 9: Sales Performance

    Sales Performance Rs. Mn Consolidated Sales Consolidated Sales Q4 FY14 YTD Dec 2013 122, 529 106, 042 26,708 28,590 Q4 2012 Q4 FY14 YTD Dec 12 YTD Dec 13  Base business sales grew over the corresponding quarter Growth calculated on Constant Forex Privileged and Confidential 9

  10. Slide 10: North America

    North America Rs. Mn Major markets 53,336 -USA -Canada 33,569 10,187 8,510 5% (43%) Q4 2012 Q4 FY14 YTD Dec 12 YTD Dec 13  Robust base business growth  Strong sales growth in Absorica™ continued Growth calculated on Constant Forex Privileged and Confidential 10

  11. Slide 11: India

    India Rs. Mn 22,395 21,346 5,794 5,342 8% 5% Q4 2012 Q4 FY14 YTD Dec 12 YTD Dec 13  Primary sales grew over the corresponding quarter  Continued strong performance in the OTC part of the business Growth calculated on Constant Forex Privileged and Confidential 11

  12. Slide 12: East Europe & CIS

    East Europe & CIS Rs. Mn Major markets 16,194 -Romania -Russia 13,160 -Ukraine 4,558 3,786 3% 10% Q4 2012 Q4 FY14 YTD Dec 12 YTD Dec 13  Sales growth led by East Europe: Romania and Poland  Ukraine sales grew in the CIS region while Russia was impacted by tender sales in the corresponding quarter

  13. Slide 13: West Europe

    West Europe Rs. Mn Major markets -France 9,720 -Germany -UK 8,346 2,248 2,348 (13%) (24%) Q4 2012 Q4 FY14 YTD Dec 12 YTD Dec 13  Regional focus on profitability continued Growth calculated on Constant Forex Privileged and Confidential 13

  14. Slide 14: Asia Pacific & Latin America

    Asia Pacific & Latin America Rs. Mn Major markets -ANZ -Malaysia 7,469 7,694 -Brazil 1,838 1,678 (16%) (2%) Q4 2012 Q4 FY14 YTD Dec 12 YTD Dec 13  Change in business model in Thailand  Sales grew in Australia, the largest market in the APAC region (ex Japan) Growth calculated on Constant Forex Pri

  15. Slide 15: Africa & Middle East

    Africa & Middle East Rs. Mn Major markets 10,917 10,188 -South Africa -Nigeria 2,838 2,648 (14%) 5% Q4 2012 Q4 FY14 YTD Dec 12 YTD Dec 13  Sales seem lower impacted by tender sales in the corresponding period Growth calculated on Constant Forex Privileged and Confidential 15

  16. Slide 16: API & Others

    API & Others Rs. Mn 7,309 6,927 2,146 1,376 (43%) (12%) Q4 2012 Q4 FY14 YTD Dec 12 YTD Dec 13  Sales impacted by lower demand Growth calculated on Constant Forex Privileged and Confidential 16

  17. Slide 17: Financials Q4 FY14: INR

    Financials Q4 FY14: INR Q4 2012 YTD Dec 12 Particulars Q4 FY14 YTD Dec 13 5,477 22,008 -Within India 5,909 22,992 21,231 100,521 -Outside India 22,681 83,050 26,708 122,529 Sales 28,590 106,042 404 2,068 Other operating income 350 1,975 27,112 124,597 Total Operating Income 28,940 108,017 11,545 40,

  18. Slide 18: Questions & Answers

    Questions & Answers Dept. Name Privileged and Confidential

Ranbaxy Laboratories — Q4 FY14 Earnings Presentation on 6ix